DC-S238 is an orally active and highly selective histone methyltransferase SET7 ( SETD7 ) inhibitor ( IC 50 =4.88 μM). DC-S238 is promising for research of cancer , diabetes and inflammatory diseases.
Products | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Signaling Pathways > Histone Methyltransferase
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.